Eyconis

CompanyUnited States

Eyconis develops one asset, in phase 1 (EYC-0305 in neovascular (wet) age-related macular degeneration). Mostly other; based in the United States.

1
Asset
Furthest stage
Phase 1
1
Trial
1
Signal

Pipeline

1
  • EYC-0305

    Phase 1, Other, neovascular (wet) age-related macular degeneration

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials1
  • Signals2

Intelligence